# CK-0045 Proof-of-concept Study in Participants With Overweight / Obesity and Type 2 Diabetes

> **NCT06611930** · PHASE2 · TERMINATED · sponsor: **Cytoki Pharma** · enrollment: 90 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)
- Obesity and Overweight

## Interventions

- **DRUG:** CK-0045
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06611930
- **Lead sponsor:** Cytoki Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-09-06
- **Primary completion:** 2025-09-06
- **Final completion:** 2025-10-21
- **Target enrollment:** 90 (ACTUAL)
- **Why stopped:** The study was terminated after the recruitment had been completed due to a decision to discontinue development of CK-0045
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06611930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06611930, "CK-0045 Proof-of-concept Study in Participants With Overweight / Obesity and Type 2 Diabetes". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT06611930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*